ADC Therapeutics SA — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$81M
Cost of Revenue
$6M
R&D
$104M
D&A
$705K
Operating Income
$-121M
EBITDA
$-121M
Interest Expense
$16M
Interest Income
$9M
Other Income/Expense
$-13M
Pretax Income
$-142M
Tax Provision
$1M
Net Income
$-143M
Operating Margin
-149.3%
Net Margin
-175.3%
Effective Tax Rate
-0.7%
Deferred Tax Assets
$789K
Deferred Tax Liabilities
$789K
DTA Valuation Allowance
$251M
NOL Carryforwards
$166M
ETR (Continuing Operations)
-0.7%
ETR Federal Statutory
7.8%
Operating Lease Cost
$1M
Pension Net Periodic Cost
$423K
Revenue YoY Variation
14.9%
Income YoY Variation
7.0%